Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Valneva ( (VALN) ) has shared an update.
On May 12, 2025, Valneva announced that the FDA and CDC recommended pausing the use of its chikungunya vaccine IXCHIQ® in elderly individuals due to ongoing investigations into serious adverse events. This follows similar precautions by the ACIP and EMA. Valneva is actively engaging with health authorities to evaluate these events and continues to support the vaccine’s use in younger populations. The company maintains that the benefits of IXCHIQ® outweigh the risks for most individuals, and it remains committed to ensuring vaccine safety.
The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects its struggle with profitability and valuation challenges. While technical indicators show a neutral to weak bullish trend, financial performance highlights ongoing hurdles in achieving positive returns. The earnings call reveals mixed results with strong revenue growth offset by operational losses and safety concerns. These factors collectively assign Valneva a below-average stock score.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is involved in developing vaccine candidates against Lyme disease, Shigella, Zika virus, and other global public health threats.
Average Trading Volume: 68,971
Technical Sentiment Signal: Sell
Current Market Cap: $531M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.